Bob Azelby has worked in biopharma for more than two decades with significant experience in the pain management space. He is currently president and CEO of Eliem Therapeutics, a biotech company focused on developing therapies for neurological conditions. Over the course of his career, he has held executive and leadership positions at Alder Biopharmaceuticals, Juno Therapeutics and Amgen.
Bob is a member of the Clovis Oncology Board of Directors and was formerly on the Immunomedics and Cascadian Therapeutics Board of Directors.
More restrictive opioid prescribing guidelines were put in place in a rightful effort to stop a devastating crisis. But this sudden and dramatic change negatively impacted chronic pain patients who were managing their pain through prescription opioids given few other effective options.